Novartis Plans $771M Investment In RTP, Bringing As Many As 700 New Jobs For Biologics, Small Molecule Manufacturing

Novartis is making a major investment in North Carolina’s Research Triangle, committing $771 million across three projects that will strengthen U.S. pharmaceutical manufacturing. The expansion includes the company’s first biologics drug substance facility in the U.S., new small molecule API production, and advanced fill/finish capabilities. These initiatives are part of a broader $23 billion plan to build a resilient domestic supply chain and ensure key medicines are produced end-to-end in the United States. With up to 700 new jobs expected by 2031 and significant local economic impact, this move underscores North Carolina’s growing role as a hub for life sciences innovation.

Explore how this investment will shape the future of biomanufacturing and workforce development in the region.